Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
NCT05263505 · Washington University School of Medicine · PHASE2 · terminated · last registry update 2023-11-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor” | – | Registry record, Washington University School of Medicine |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against JAK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-29Results posted on the registry: Mayo Clinic, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter + Ruxolitinib Phosphate (NCT03120624)
- 2024-10-28Results posted on the registry: Novartis Pharmaceuticals, Pelabresib + Ruxolitinib (NCT04603495)
- 2024-10-23Phase 3 first posted: Duke University, TNFi (Tumor Necrosis Factor inhibitor) medication + Abatacept (NCT06654882)
- 2024-10-08Phase 3 first posted: Wes Ely, Baricitinib (NCT06631287)
- 2024-09-26Phase 3 first posted: Incyte Corporation, Tacrolimus (Tac) + Methotrexate (MTX) (NCT06615050)
- 2024-08-13Results posted on the registry: Eli Lilly and Company, Baricitinib + Adalimumab (NCT04088409)
- 2024-08-12Phase 3 first posted: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT06548360)
- 2024-07-30Results posted on the registry: Children's Hospital Medical Center, Cincinnati, Tofacitinib (NCT03288324)
- 2024-06-17Phase 3 first posted: AbbVie, Upadacitinib + Dupilumab (NCT06461897)
- 2024-05-28Phase 3 first posted: Priovant Therapeutics, Inc., Brepocitinib PO QD + Placebo PO QD (NCT06431373)
- 2024-05-14Results posted on the registry: Eli Lilly and Company, Baricitinib + Placebo (NCT03899259)
- 2024-04-29Phase 3 first posted: AbbVie, Upadacitinib 15mg Dose + Dupilumab 300mg Dose (NCT06389136)
- 2024-04-18Results posted on the registry: Dana-Farber Cancer Institute, Ruxolitinib + Paclitaxel (NCT02876302)
- 2024-03-27Phase 3 first posted: AbbVie, Upadacitinib (NCT06332534)
- 2024-03-05Results posted on the registry: Fred Hutchinson Cancer Center, Busulfan + Cyclophosphamide (NCT02251821)
- 2024-02-02Phase 3 first posted: Incyte Corporation, Ruxolitinib Cream + Vehicle Cream (NCT06238817)
- 2024-01-29Phase 3 first posted: Takeda, Vedolizumab + Upadacitinib (NCT06227910)
- 2023-12-15Phase 3 first posted: Zhejiang University, Prednisone+Tofacitinib + Prednisone (NCT06172361)
- 2023-11-07Phase 3 first posted: AbbVie, Upadacitinib + Placebo (NCT06118411)
- 2023-10-17Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Ruxolitinib (NCT03722407)
- 2023-10-12Phase 3 first posted: Merck Sharp & Dohme LLC, Bomedemstat + Anagrelide (NCT06079879)
- 2023-08-31Phase 3 first posted: Hangzhou Highlightll Pharmaceutical Co., Ltd, TLL-018 + Tofacitinib (NCT06020144)
- 2023-08-25Phase 3 first posted: AbbVie, Upadacitinib + Placebo (NCT06012240)
- 2023-06-29Results posted on the registry: Eli Lilly and Company, Baricitinib + Placebo (NCT03952559)
- 2023-06-05Phase 3 first posted: AbbVie, Upadacitinib + Placebo (NCT05889182)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision